Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (541-550 of 688) with videos related to

Pageof 69
Sort By:
European Heart Journal|April 9, 2026
Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trialsJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JACC. Heart Failure|March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT TrialMuthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
JAMA Cardiology|June 3, 2026
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical TrialsKevin Bryan Lo, John W Ostrominski, Yasuhiro Hamatani, et al.
European Journal of Heart Failure|May 15, 2024
On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HFVeraprapas Kittipibul, Robert J Mentz, Robert M Clare, et al.
JACC. Heart Failure|July 15, 2019
Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Sara B Seidelmann, Brian Claggett, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
Journal of Cardiac Failure|May 21, 2025
Effects of Finerenone on Readmissions for Heart Failure: Insights from the FINEARTS-HF TrialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
The American Journal of Medicine|April 5, 2023
Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney DiseaseSamir Patel, Phillip H Lam, Evangelos I Kanonidis, et al.
Clinical Kidney Journal|March 3, 2023
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney diseaseRajiv Agarwal, Bertram Pitt, Biff F Palmer, et al.
Pageof 69

Showing results (541-550 of 688) with videos related to

Sort By:
Pageof 69
European Heart Journal|April 9, 2026
Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trialsJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
JACC. Heart Failure|March 5, 2018
Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT TrialMuthiah Vaduganathan, Brian L Claggett, Neal A Chatterjee, et al.
JAMA Cardiology|June 3, 2026
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical TrialsKevin Bryan Lo, John W Ostrominski, Yasuhiro Hamatani, et al.
European Journal of Heart Failure|May 15, 2024
On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HFVeraprapas Kittipibul, Robert J Mentz, Robert M Clare, et al.
JACC. Heart Failure|July 15, 2019
Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Sara B Seidelmann, Brian Claggett, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
Journal of Cardiac Failure|May 21, 2025
Effects of Finerenone on Readmissions for Heart Failure: Insights from the FINEARTS-HF TrialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 16, 2018
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT TrialMaja Cikes, Brian Claggett, Amil M Shah, et al.
The American Journal of Medicine|April 5, 2023
Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney DiseaseSamir Patel, Phillip H Lam, Evangelos I Kanonidis, et al.
Clinical Kidney Journal|March 3, 2023
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney diseaseRajiv Agarwal, Bertram Pitt, Biff F Palmer, et al.
Pageof 69